AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology

AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Turnstone Biologics, a clinical-stage immuno-oncology company, have announced a research, option and license agreement whereby AbbVie obtained an exclusive option to license up to three of Turnstone's next-generation oncolytic viral immunotherapies.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured AbbVie Business and Industry Source Type: news